Surgery Branch, CCR
National Cancer Institute
United States of America
Dr. Ken-ichi Hanada received M.D. degree at Tokyo Medical and Dental University and a Ph.D. at the University of Tokyo, Japan. He joined the Surgery Branch, NCI in 1997 as a visiting scientist and became a staff scientist in 2005. He has been involved in the basic studies of immune response to renal cell carcinoma and also in the development of clinical trials for renal cell carcinoma.
Renal cell carcinoma, CD8+ tumor-reactive repertoire infiltrating human tumors, Cancer immunotherapy.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Double or nothing on cancer immunotherapy.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.